Literature DB >> 1657106

Iron status markers in patients with small cell carcinoma of the lung. Relation to survival.

N Milman1, H Sengeløv, P Dombernowsky.   

Abstract

A longitudinal study of iron status markers (haemoglobin (Hb), serum (S-) iron, S-transferrin, transferrin saturation, S-ferritin) was performed in 31 chemotherapy treated patients with small cell lung cancer. At discovery, eight patients were anaemic (Hb less than 121 g l-1). Hb, S-iron and transferrin saturation were lower (P less than 0.01), and S-ferritin higher (P less than 0.01) than in healthy subjects. Chemotherapy induced an immediate fall in Hb (P less than 0.003), increase in S-iron (P less than 0.003) and transferrin saturation (P less than 0.001). Later in the disease a fall in S-transferrin (P less than 0.006) and an increase in S-ferritin (P less than 0.02) occurred. Thirty patients died during the 2 years observation. S-ferritin at discovery was correlated to performance status score (r = 0.57, P = 0.01) and to survival (r = -0.63, P less than 0.0002). Patients with S-ferritin less than or equal to 400 micrograms l-1 (n = 13) had longer survival than those with S-ferritin greater than 400 micrograms l-1 (n = 18) (P = 0.004).

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1657106      PMCID: PMC1977453          DOI: 10.1038/bjc.1991.421

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Combination chemotherapy of limited-stage small-cell lung cancer. A controlled trial on 221 patients comparing two alternating regimens.

Authors:  K Osterlind; M Hansen; F R Hirsch; P Dombernowsky; S Sörenson; A G Pedersen; H H Hansen
Journal:  Ann Oncol       Date:  1991-01       Impact factor: 32.976

2.  Changes in serum iron levels following very high-dose cisplatin.

Authors:  C F Pollera; F Ameglio; S Reina; M Nardi; M R Abbolito; C Parracino
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  Serum ferritin concentration and iron stores in normal subjects.

Authors:  G O Walters; F M Miller; M Worwood
Journal:  J Clin Pathol       Date:  1973-10       Impact factor: 3.411

4.  Some factors affecting the release of iron from reticuloendothelial cells.

Authors:  D A Lipschitz; M O Simon; S R Lynch; J Dugard; T H Bothwell; R W Charlton
Journal:  Br J Haematol       Date:  1971-09       Impact factor: 6.998

5.  Immunologic differences in human isoferritins: implications for immunologic quantitation of serum ferritin.

Authors:  J T Hazard; M Yokota; P Arosio; J W Drysdale
Journal:  Blood       Date:  1977-01       Impact factor: 22.113

Review 6.  Chemotherapeutic agents and the erythron.

Authors:  D C Doll; R B Weiss
Journal:  Cancer Treat Rev       Date:  1983-09       Impact factor: 12.111

7.  Serum ferritin in healthy Danes: relation to marrow haemosiderin iron stores.

Authors:  N Milman; N S Pedersen; J Visfeldt
Journal:  Dan Med Bull       Date:  1983-03

8.  Serum transferrin and ceruloplasmin concentrations in patients with carcinoma, melanoma, sarcoma and cancers of haematopoietic tissues.

Authors:  N R Hughes
Journal:  Aust J Exp Biol Med Sci       Date:  1972-02

9.  Serum ferritin levels in small cell lung cancer.

Authors:  R Cox; O H Gyde; M J Leyland
Journal:  Eur J Cancer Clin Oncol       Date:  1986-07

10.  Carcinoembryonic antigen and ferritin in patients with lung cancer before and during therapy.

Authors:  C Gropp; K Havemann; F G Lehmann
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

View more
  2 in total

1.  Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer.

Authors:  Sookyung Lee; Wankyu Eo; Hyeonjin Jeon; Sora Park; Jean Chae
Journal:  J Cancer       Date:  2017-08-25       Impact factor: 4.207

2.  Iron levels, genes involved in iron metabolism and antioxidative processes and lung cancer incidence.

Authors:  Grzegorz Mariusz Sukiennicki; Wojciech Marciniak; Magdalena Muszyńska; Piotr Baszuk; Satish Gupta; Katarzyna Białkowska; Katarzyna Jaworska-Bieniek; Katarzyna Durda; Marcin Lener; Sandra Pietrzak; Tomasz Gromowski; Karolina Prajzendanc; Alicja Łukomska; Piotr Waloszczyk; Janusz Zenon Wójcik; Rodney Scott; Jan Lubiński; Anna Jakubowska
Journal:  PLoS One       Date:  2019-01-14       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.